This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

CAMHS won't see you now

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.

Report comment to moderator

Required fields.

Headline

GPs 'should prescribe statins to younger patients' using 30-year risk score

Comment

If you do phase 3 trials, you realize that all CRO and Clinical Monitors are under enormous pressure to get things done and to get the 'right data'. That might be the reason why some drugs slip through the loop and get registered as being effective while some important side effect profiles get hazy and omitted. The money per patient recruited can be anything from a few 100 to 5000 pounds per patient recruited according to the condition and the prospective price of the money. Launching a product can cost up to £500 million so the money has to come from somewhere. Is that why we keep coming under pressure from pseudo researchers to carry on increasing prescribing?

Posted date

22 Nov 2018

Posted time

10:45am

required
required
required